Proteasome inhibitor lactacystin induces cholinergic degeneration

Canadian Journal of Neurological Sciences

Volumn 37, Issue 2, 2010, Pages 229-234

  Zhou, Hai Yan ^a   Tan, Yu Yan ^a   Wang, Zhi Quan ^b   Wang, Gang ^a   Lu, Guo Qiang ^a   Chen, Sheng Di ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; LACTACYSTIN; PROTEASOME; PROTEIN; REACTIVE OXYGEN METABOLITE; UBIQUITIN;

ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CELL LOSS; CELL VIABILITY; CHOLINERGIC NERVE CELL; DOPAMINERGIC NERVE CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 76649131572     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009975     Document Type: Article

References (39)

1. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302 (5646):819-822
2. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol. 2003;53 Suppl 3:S73-84.
3. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005;28:57-87.
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321): 2045-2047
5. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392 (6676):605-608
6. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395 (6701):451-452
7. Bonifati V, Rizzu P, Van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003; 299(5604):256-259
8. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett. 2001;297 (3):191-194
9. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett. 2002; 326(3):155-158
10. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol. 2003;179(1):38-46.
11. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci. 2003;23(26):8955-8966
12. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol. 2004;56(1):149-162
13. Schapira AH, Cleeter MW, Muddle JR, Workman JM, Cooper JM, King RH. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol. 2006;60(2):253-255
14. Mathur BN, Neely MD, Dyllick-Brenzinger M, Tandon A, Deutch AY. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 2007; 1168:83-89
15. Landau AM, Kouassi E, Siegrist-Johnstone R, Desbarats J. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov Disord. 2007;22(3):403-407
16. Kordower JH, Kanaan NM, Chu Y, Suresh Babu R, Stansell J 3rd, Terpstra BT, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006;60(2):264-268
17. Manning-Bo AB, Reaney SH, Chou VP, Johnston LC, McCormack AL, Johnston J, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol. 2006;(2):256-260
18. Hawlitschka A, Haas SJ, Schmitt O, Weiss DG, Wree A. Effects of systemic PSI administration on catecholaminergic cells in the brain,adrenal medulla and carotid body inWistar rats. Brain Res. 2007;1173:137-144
19. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
20. Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord. 2005;20(3):271-282
21. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003; 60(3):337-341
22. Rideout HJ, Lang-Rollin IC, Savalle M, Stefanis L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem. 2005;93(5): 1304-1313
23. Suh J, Lee YA, Gwag BJ. Induction and attenuation of neuronal apoptosis by proteasome inhibitors in murine cortical cell cultures. J Neurochem. 2005;95(3):684-694
24. Lang-Rollin I, Vekrellis K, Wang Q, Rideout HJ, Stefanis L. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem. 2004;90(6):1511-1520
25. Qiu JH, Asai A, Chi S, Saito N, Hamada H, Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like proteasemediated apoptosis in cultured cortical neurons. J Neurosci. 2000;20(1):259-265
26. Sullivan PG, Dragicevic NB, Deng JH, Bai Y, Dimayuga E, Ding Q, et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem. 2004;279 (20):20699-20707
27. Wagenknecht B, Hermisson M, Groskurth P, Liston P, Krammer PH,Weller M. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem. 2000;75(6):2288-2297
28. Goldbaum O, Vollmer G, Richter-Landsberg C. Proteasome inhibition by MG-132 induces apoptotic cell death and mitochondrial dysfunction in cultured rat brain oligodendrocytes but not in astrocytes. Glia. 2006;53(8):891-901.
29. Halliwell B. Hypothesis: proteasomal dysfunction: a primary event in neurodegeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann N YAcad Sci. 2002;962:182-194
30. Kikuchi S, Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, et al. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res. 2003;964(2):228-236
31. Mytilineou C, McNaught KS, Shashidharan P, Yabut J, Baptiste RJ, Parnandi A, et al. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm. 2004;111(10-11):1237- 1251
32. Lev N, Melamed E, Offen D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett. 2006;399(1-2):27-32.
33. Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, et al. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem. 2007;282(7):4364-4372
34. Hung CC, Davison EJ, Robinson PA, Ardley HC. The aggravating role of the ubiquitin-proteasome system in neurodegenerative disease. Biochem Soc Trans. 2006;34(Pt 5):743-745
35. Ardley HC, Hung CC, Robinson PA. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett. 2005;579(3):571-576
36. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, et al. Immumohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol. 1999;45(5):668-672
37. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002; 160(5):1655-1667
38. Rideout HJ,Wang Q, Park DS, Stefanis L. Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci. 2003;23(4):1237-1245
39. Dietrich P, Rideout HJ, Wang Q, Stefanis L. Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons. Mol Cell Neurosci. 2003;24(2):430-441